Novel Approaches for the Treatment of Familial Hypercholesterolemia: Current Status and Future Challenges

Area of Science:

• Cardiovascular Genetics
• Molecular Medicine
• Biotechnology

Background:

• Familial hypercholesterolemia (FH) is an inherited condition causing severely elevated LDL cholesterol and premature cardiovascular disease.
• Current treatments like statins and PCSK9 inhibitors are often insufficient for homozygous FH patients.
• Gene therapy presents a novel therapeutic strategy for managing FH.

Purpose of the Study:

• To review the current landscape of gene therapy approaches for familial hypercholesterolemia.
• To highlight recent advancements and their potential impact on clinical applications for FH treatment.

Main Methods:

• Exploration of adeno-associated virus (AAV) vector-based gene therapy.
• Review of antisense oligonucleotide (ASO) and small interfering RNA (siRNA) therapies.
• Investigation of emerging technologies like CRISPR/Cas9, minicircle DNA, microRNAs, and long non-coding RNAs.

Main Results:

• AAV8 vectors expressing the LDL receptor gene show efficacy in preclinical models and are in clinical trials.
• ASO and siRNA therapies are progressing through early-phase clinical trials.
• Novel gene-editing and RNA-based strategies demonstrate significant therapeutic potential for FH.

Conclusions:

• Gene therapy holds considerable promise for treating FH, offering new hope for patients with refractory hypercholesterolemia.
• Delivery systems, immunogenicity, and specificity are key challenges to address for successful clinical translation.
• Continued research and development in gene therapy are crucial for advancing FH treatment options.